Evaluation of lipid profile, macular toxicity and clinical manifestations according to APO E genotype in systemic lupus erythematosus and rheumatoid arthritis patients treated with chloroquine.
OBJECTIVE
To investigate the effect of APO E gene polymorphism over lipid profile, macular toxicity and clinical manifestations in RA and SLE patients treated with chloroquine.


METHODS
We studied 45 RA and 29 SLE patients treated with chloroquine who were classified based on the therapeutic regime of chloroquine into three groups: A) Cumulative dose of 100-300 g, B) >300 g and C) Never received chloroquine. Clinical evaluation, fasting lipid profile, visual field testing and stereoscopic photos of the retina were performed. APO E genotype was determined by PCR-RFLP.


RESULTS
Reduced apo B levels in RA and SLE according to the cumulative dose of chloroquine 2/3 APO E genotype in a subset of SLE patients were observed. Macular toxicity was independent of both APO E genotype and cumulative chloroquine dose.


CONCLUSIONS
Reduced apo B levels were observed associated to chloroquine treatment and 2/3 APO E genotype.
Vázquez-Del Mercado
M
M
Instituto de Biología Molecular en Medicina, C.U.C.S., U. de G., México. vmebest@hotmail.com
Muñoz-Valle
J F
JF
Santos
A
A
Bernard-Medina
A G
AG
Martínez-Bonilla
G
G
Paczka
J A
JA
Ruiz-García
H
H
Orozco-Alcalá
J
J
Orozco-Barocio
G
G
Quezada-Arellano
D
D
Gurrola-Díaz
C
C
Nuño-González
P
P
Best-Aguilera
C R
CR
Chávez-Castellanos
R
R
Panduro
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001057:Apolipoproteins E / Q000235:genetics*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D002738:Chloroquine / Q000009:adverse effects*; D004247:DNA / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000188:drug therapy / Q000235:genetics*; D008266:Macula Lutea / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009887:Ophthalmoscopy; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D012164:Retinal Diseases / Q000139:chemically induced*; D012189:Retrospective Studies
D018501:Antirheumatic Agents; D001057:Apolipoproteins E; D008055:Lipids; D002738:Chloroquine; D004247:DNA